Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Fundamentals Of Care for UveitiS (FOCUS) Initiative

Andrew D. Dick, James (Jim) Rosenbaum, Hassan A. Al-Dhibi, Rubens Belfort, Antoine P. Brézin, Soon Phaik Chee, Janet L. Davis, Athimalaipet V. Ramanan, Koh Hei Sonoda, Ester Carreño, Heloisa Nascimento, Sawsen Salah, Sherveen Salek, Jay Siak, Eric Suhler

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.

Original languageEnglish (US)
JournalOphthalmology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Immunomodulation
Uveitis
Biological Factors
Guidelines
Consensus
Delphi Technique
Therapeutics
Safety
Pharmaceutical Economics
Eye Diseases
Practice Management
Expert Testimony
Biological Products
Libraries
Publications
Meta-Analysis
Decision Making
Language
Randomized Controlled Trials
Retrospective Studies

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Fundamentals Of Care for UveitiS (FOCUS) Initiative. / Dick, Andrew D.; Rosenbaum, James (Jim); Al-Dhibi, Hassan A.; Belfort, Rubens; Brézin, Antoine P.; Chee, Soon Phaik; Davis, Janet L.; Ramanan, Athimalaipet V.; Sonoda, Koh Hei; Carreño, Ester; Nascimento, Heloisa; Salah, Sawsen; Salek, Sherveen; Siak, Jay; Suhler, Eric.

In: Ophthalmology, 01.01.2018.

Research output: Contribution to journalArticle

Dick, AD, Rosenbaum, JJ, Al-Dhibi, HA, Belfort, R, Brézin, AP, Chee, SP, Davis, JL, Ramanan, AV, Sonoda, KH, Carreño, E, Nascimento, H, Salah, S, Salek, S, Siak, J & Suhler, E 2018, 'Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Fundamentals Of Care for UveitiS (FOCUS) Initiative', Ophthalmology. https://doi.org/10.1016/j.ophtha.2017.11.017
Dick, Andrew D. ; Rosenbaum, James (Jim) ; Al-Dhibi, Hassan A. ; Belfort, Rubens ; Brézin, Antoine P. ; Chee, Soon Phaik ; Davis, Janet L. ; Ramanan, Athimalaipet V. ; Sonoda, Koh Hei ; Carreño, Ester ; Nascimento, Heloisa ; Salah, Sawsen ; Salek, Sherveen ; Siak, Jay ; Suhler, Eric. / Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Fundamentals Of Care for UveitiS (FOCUS) Initiative. In: Ophthalmology. 2018.
@article{40920ae53d27459d8adc01bd6cc2c09f,
title = "Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Fundamentals Of Care for UveitiS (FOCUS) Initiative",
abstract = "Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.",
author = "Dick, {Andrew D.} and Rosenbaum, {James (Jim)} and Al-Dhibi, {Hassan A.} and Rubens Belfort and Br{\'e}zin, {Antoine P.} and Chee, {Soon Phaik} and Davis, {Janet L.} and Ramanan, {Athimalaipet V.} and Sonoda, {Koh Hei} and Ester Carre{\~n}o and Heloisa Nascimento and Sawsen Salah and Sherveen Salek and Jay Siak and Eric Suhler",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ophtha.2017.11.017",
language = "English (US)",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis. Fundamentals Of Care for UveitiS (FOCUS) Initiative

AU - Dick, Andrew D.

AU - Rosenbaum, James (Jim)

AU - Al-Dhibi, Hassan A.

AU - Belfort, Rubens

AU - Brézin, Antoine P.

AU - Chee, Soon Phaik

AU - Davis, Janet L.

AU - Ramanan, Athimalaipet V.

AU - Sonoda, Koh Hei

AU - Carreño, Ester

AU - Nascimento, Heloisa

AU - Salah, Sawsen

AU - Salek, Sherveen

AU - Siak, Jay

AU - Suhler, Eric

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.

AB - Topic: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. Clinical Relevance: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. Methods: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science). Publications included randomized controlled trials, prospective and retrospective studies with sufficient follow-up, case series with 15 cases or more, peer-reviewed articles, and hand-searched conference abstracts from key conferences. The proposed statements were circulated among 130 international uveitis experts for review. A total of 44 globally representative group members met in late 2016 to refine these guidelines using a modified Delphi technique and assigned Oxford levels of evidence. Results: In total, 10 questions were addressed resulting in 21 evidence-based guidance statements covering the following topics: when to start noncorticosteroid immunomodulatory therapy, including both biologic and nonbiologic agents; what data to collect before treatment; when to modify or withdraw treatment; how to select agents based on individual efficacy and safety profiles; and evidence in specific uveitic conditions. Shared decision-making, communication among providers and safety monitoring also were addressed as part of the recommendations. Pharmacoeconomic considerations were not addressed. Conclusions: Consensus guidelines were developed based on published literature, expert opinion, and practical experience to bridge the gap between clinical needs and medical evidence to support the treatment of patients with noninfectious uveitis with noncorticosteroid immunomodulatory agents.

UR - http://www.scopus.com/inward/record.url?scp=85039978698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039978698&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2017.11.017

DO - 10.1016/j.ophtha.2017.11.017

M3 - Article

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

ER -